Neurocrine Biosciences, Inc. NBIX | NASDAQ
Next Earnings: May 05, 2025
Company Overview:
6.3 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
NBIX Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for NBIX
Based on past 6.3-year performance, here are NBIX growth metrics:
Share price CAGR of +3.05%
Dividend CAGR of +0%
Using NBIX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| NBIX (DRIP) | NBIX - No DRIP | |
|---|---|---|
| Current Price | $106.59 | $106.59 |
| Start Shares | 93.82 | 93.82 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 93.82 | 93.82 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $139.66 | $106.59 |
| Total Dividends | $0 | $0 |
| Final Value | $13,103 | $10,000 |
NOTE: Above numbers are our estimate based on NBIX's Dividend and Price CAGR over past 6.3 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Neurocrine Biosciences, Inc. (NBIX) had its IPO on 1996-05-23, and is trader on NASDAQ stock exchange.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX website: https://www.neurocrine.com
